Technical Analysis for KMPH - KemPharm, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
2.29 | -0.43% | -0.01 |
KMPH closed down 0.43 percent on Tuesday, February 19, 2019, on 33 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical KMPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Feb 19 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Feb 19 | Outside Day | Range Expansion | 0.00% |
| Feb 19 | Down 3 Days in a Row | Weakness | 0.00% |
| Feb 19 | Oversold Stochastic | Weakness | 0.00% |
| Feb 15 | Lower Bollinger Band Walk | Weakness | -0.43% |
| Feb 15 | Lower Bollinger Band Touch | Weakness | -0.43% |
| Feb 15 | Oversold Stochastic | Weakness | -0.43% |
| Feb 14 | MACD Bearish Centerline Cross | Bearish | -2.14% |
| Feb 14 | Lower Bollinger Band Walk | Weakness | -2.14% |
| Feb 14 | Lower Bollinger Band Touch | Weakness | -2.14% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-04-04
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
Health Pharmaceutical Pharmaceutical Industry Pain Medication FDA Pharmacokinetics Platform Technology Attention Deficit Hyperactivity Disorder Adhd Amphetamine Methylphenidate
Health Pharmaceutical Pharmaceutical Industry Pain Medication FDA Pharmacokinetics Platform Technology Attention Deficit Hyperactivity Disorder Adhd Amphetamine Methylphenidate
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more KMPH news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 8.4 |
| 52 Week Low | 1.715 |
| Average Volume | 149,804 |
| 200-Day Moving Average | 4.0117 |
| 50-Day Moving Average | 2.4298 |
| 20-Day Moving Average | 2.5798 |
| 10-Day Moving Average | 2.445 |
| Average True Range | 0.1673 |
| ADX | 17.44 |
| +DI | 13.0923 |
| -DI | 16.7421 |
| Chandelier Exit (Long, 3 ATRs ) | 2.3481 |
| Chandelier Exit (Short, 3 ATRs ) | 2.7519 |
| Upper Bollinger Band | 2.9177 |
| Lower Bollinger Band | 2.2419 |
| Percent B (%b) | 0.07 |
| BandWidth | 26.195829 |
| MACD Line | -0.0427 |
| MACD Signal Line | 0.0103 |
| MACD Histogram | -0.0531 |
| Fundamentals | Value |
|---|---|
| Market Cap | 33.56 Million |
| Num Shares | 14.7 Million |
| EPS | -3.10 |
| Price-to-Earnings (P/E) Ratio | -0.74 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.49 | ||||
| Resistance 3 (R3) | 2.49 | 2.44 | 2.45 | ||
| Resistance 2 (R2) | 2.44 | 2.39 | 2.43 | 2.44 | |
| Resistance 1 (R1) | 2.36 | 2.36 | 2.40 | 2.36 | 2.43 |
| Pivot Point | 2.31 | 2.31 | 2.33 | 2.30 | 2.31 |
| Support 1 (S1) | 2.23 | 2.26 | 2.27 | 2.23 | 2.15 |
| Support 2 (S2) | 2.18 | 2.23 | 2.17 | 2.14 | |
| Support 3 (S3) | 2.10 | 2.18 | 2.13 | ||
| Support 4 (S4) | 2.10 |
